The estimated Net Worth of Gary S Roubin is at least $1.18 millió dollars as of 30 November 2023. Gary Roubin owns over 50,000 units of InspireMD Inc stock worth over $1,176,257 and over the last 4 years he sold NSPR stock worth over $0. In addition, he makes $0 as Director at InspireMD Inc.
Sign up
Gary Roubin NSPR stock SEC Form 4 insiders trading
Gary has made over 8 trades of the InspireMD Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of NSPR stock worth $126,500 on 30 November 2023.
The largest trade he's ever made was buying 241,930 units of InspireMD Inc stock on 8 February 2021 worth over $149,997. On average, Gary trades about 39,734 units every 67 days since 2020. As of 30 November 2023 he still owns at least 438,902 units of InspireMD Inc stock.
You can see the complete history of Gary Roubin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gary Roubin biography
Dr. Gary S. Roubin M.D., Ph.D. serves as Director of the Company. Dr. Roubin attended medical school at the University of Queensland where he completed his degree in 1975. After completing his cardiology training, he enrolled as a Ph.D. candidate at Sydney University and was awarded this degree in 1983. He then joined Andreas Gruentzig at Emory University to continue his post-doctoral research. In October of 1987, he developed and placed the world’s first balloon expandable coronary stent. In 1989, he moved to the University of Alabama at Birmingham, where he was Professor of Medicine and Radiology and Director of the Cardiac Catheterization Laboratories and Interventional Cardiology Section at the University of Alabama Hospital. Dr. Roubin has co-authored more than 280 papers and 225 abstracts in peer reviewed journals. He has also edited three textbooks on interventional cardiovascular medicine, coronary, and carotid artery stenting and contributed to 20 textbooks on interventional cardiology and vascular medicine. His book “The First Balloon Expandable Coronary Stent: An Expedition that Changed Cardiovascular Medicine” was published in 2015. He lectures extensively in the United States and abroad and has received numerous national and international awards for his notable contributions to cardiac and vascular care. Dr. Roubin has been on record for the last decade advocating the use of optimally designed “fine mesh” stents to further reduce the risk of embolic complications from CAS.
What's Gary Roubin's mailing address?
Gary's mailing address filed with the SEC is C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV, L3, 6744832.
Insiders trading at InspireMD Inc
Over the last 13 years, insiders at InspireMD Inc have traded over $1,684,082 worth of InspireMD Inc stock and bought 3,887,125 units worth $5,293,286 . The most active insiders traders include Sol J Barer, Eli Bar és Gary S Roubin. On average, InspireMD Inc executives and independent directors trade stock every 97 days with the average trade being worth of $319,459. The most recent stock trade was executed by Gary S Roubin on 30 November 2023, trading 50,000 units of NSPR stock currently worth $126,500.
What does InspireMD Inc do?
inspiremd, inc. is a company based out of 800 boylston street suite 16041, boston, massachusetts, united states.
What does InspireMD Inc's logo look like?
Complete history of Gary Roubin stock trades at InspireMD Inc
InspireMD Inc executives and stock owners
InspireMD Inc executives and other stock owners filed with the SEC include:
-
Marvin L. Slosman,
Pres, CEO & Director -
Craig Shore,
CFO, Chief Admin. Officer, Sec. & Treasurer -
Craig Shore,
Chief Financial Officer, Chief Administrative Officer, Treasurer and Secretary -
Campbell Rogers,
Independent Director -
Michael Berman,
Independent Director -
Gary Roubin,
Director -
Thomas Kester,
Director -
Agustin Gago,
Executive Vice President, Chief Commercial Officer -
Isaac Blech,
Independent Vice Chairman of the Board -
Marvin Slosman,
Chief Executive Officer, Director -
Paul Stuka,
Chairman of the Board -
Dr. Sol J. Barer Ph.D.,
Special Advisor to the Board -
Amir Kohen,
VP of Fin. & International HR -
Andrea Tommasoli,
Sr. VP of Global Sales & Marketing -
Roei Samuri,
VP of Operations -
Sol J Barer,
Director -
James J Barry,
President and CEO -
James J Loughlin,
Director -
Alan Milinazzo,
President and CEO -
Eric L. Olson,
VP of Global Sales Operations -
Eli Bar,
CTO InspireMD Ltd. -
Asher Holzer,
Director -
Eyal Weinstein,
Director -
Kathryn Arnold,
Director -
Shane Thomas Gleason,
Chief Commercial Officer -
Patrick Verta,
EVP Clinical/Medical Affairs